Analisis Keuangan Saham PRRUF - Immutep Limited (OTCPK) Stock

Immutep Limited
US ˙ OTCPK

Gambaran Umum
Immutep Limited is an Australian biotechnology company that specializes in the development of immunotherapy treatments for cancer and autoimmune diseases. Founded in 1987 and headquartered in Sydney, Immutep is at the forefront of advancing immunotherapeutic products that harness the body’s immune system. Its key projects focus on the proprietary LAG-3 (Lymphocyte Activation Gene-3) technology, which has yielded multiple product candidates, including eftilagimod alpha (IMP321), positioned as a potential enhancer of the immune response to various tumors. Additionally, Immutep’s pipeline includes multiple partnerships with major pharmaceutical companies aimed at co-developing and commercializing their immunotherapeutic compounds, demonstrating significant investment in research and potential for growth in oncology and beyond.
Skor Kualitas, Nilai, dan Momentum

Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.

Kualitas

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Nilai

Model penilaian eksklusif yang memberi peringkat pada perusahaan berdasarkan valuasi relatifnya. Skor berkisar antara 0 hingga 100, dengan 100 sebagai yang paling diremehkan nilainya.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Sentimen Dana

Skor Sentimen Dana (sebelumnya dikenal sebagai Skor Kepemilikan) adalah model kuantitatif eksklusif yang memberi peringkat pada perusahaan berdasarkan tingkat akumulasi kepemilikan.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
  • Nilai revenue untuk Immutep Limited per 2025 Jun 30 adalah 5.04 MM.
  • Nilai operating income untuk Immutep Limited per 2025 Jun 30 adalah -65.01 MM.
  • Nilai net income untuk Immutep Limited per 2025 Jun 30 adalah -61.43 MM.
Period End (TTM) Revenue (MM) Operating Income (MM) Net Income (MM)
2025-06-30 5.04 -65.01 -61.43
2025-03-31 4.96 -57.43 -52.65
2024-12-31 4.88 -49.85 -43.87
2024-09-30 4.36 -48.20 -43.29
2024-06-30 3.84 -46.56 -42.72
2024-03-31 3.89 -44.85 -41.61
2023-12-31 3.93 -43.14 -40.50
2023-09-30 3.72 -42.28 -40.20
2023-06-30 3.51 -41.43 -39.90
2023-03-31 3.91 -39.92 -38.23
2022-12-31 4.32 -38.42 -36.56
2022-09-30 4.52 -36.13 -34.39
2022-06-30 4.71 -33.84 -32.21
2022-03-31 4.22 -29.97 -29.27
2021-12-31 3.73 -26.11 -26.33
2021-09-30 3.80 -22.88 -28.12
2021-06-30 3.86 -19.66 -29.90
2021-03-31 5.11 -19.38 -28.63
2020-12-31 6.35 -19.11 -27.36
2020-09-30 10.05 -17.09 -20.42
2020-06-30
2020-03-31
Laporan Laba Rugi: EPS
Period End (TTM) Earnings Per Share Basic Earnings Per Share Diluted
2025-06-30
2025-03-31
2024-12-31 -0.03 -0.03
2024-09-30 -0.03 -0.03
2024-06-30 -0.04 -0.04
2024-03-31 -0.04 -0.04
2023-12-31 -0.04 -0.04
2023-09-30 -0.04 -0.04
2023-06-30 -0.04 -0.04
2023-03-31 -0.04 -0.04
2022-12-31 -0.04 -0.04
2022-09-30 -0.04 -0.04
2022-06-30 -0.04 -0.04
2022-03-31 -0.04 -0.04
2021-12-31 -0.03 -0.03
2021-09-30 -0.04 -0.04
2021-06-30 -0.05 -0.05
2021-03-31 -0.05 -0.05
2020-12-31 -0.06 -0.06
2020-09-30 -0.05 -0.05
2020-06-30 -0.03 -0.03
2020-03-31 -0.04 -0.04
Arus Kas: Operasi, Investasi, Pendanaan
  • Nilai cash from operating activities untuk Immutep Limited per 2025 Jun 30 adalah -62.05 MM.
  • Nilai cash from investing activities untuk Immutep Limited per 2025 Jun 30 adalah -38.53 MM.
  • Nilai kas dari aktivitas pendanaan untuk Immutep Limited per 2025 Jun 30 adalah -0.53 MM.
Period End (TTM) Cash From Operating Activities (MM) Cash From Investing Activities (MM) Cash From Financing Activities (MM)
2025-06-30 -62.05 -38.53 -0.53
2025-03-31 -53.48 -60.97 47.33
2024-12-31 -44.92 -83.41 95.18
2024-09-30 -39.87 -52.22 95.18
2024-06-30 -34.82 -21.02 95.18
2024-03-31 -38.36 -10.73 85.44
2023-12-31 -41.89 -0.44 75.70
2023-09-30 -38.62 -0.26 75.86
2023-06-30 -35.36 -0.08 76.02
2023-03-31 -32.86 -0.08 37.90
2022-12-31 -30.36 -0.08 -0.21
2022-09-30 -30.29 -0.05 25.06
2022-06-30 -30.23 -0.02 50.33
2022-03-31 -25.31 -0.02 57.40
2021-12-31 -20.39 -0.02 64.48
2021-09-30 -19.02 -0.02 58.58
2021-06-30 -17.64 -0.02 52.68
2021-03-31 -16.16 -0.01 51.30
2020-12-31 -14.67 -0.01 49.92
2020-09-30 -12.76 -0.01 35.20
2020-06-30
2020-03-31
Metrik Penilaian: PE, PriceToBook, PriceToTBV
P/Book
The current closing price divided by the book value per share.
P/TBV
The current price divided by the tangible book value per share.
Period End (TTM) p/e P/Book P/TBV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
Period End (TTM) EBIT/EV EBIT (3y)/EV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
Efektivitas Manajemen
  • roa untuk Immutep Limited pada 2025 Jun 30 adalah -0.22.
  • roe untuk Immutep Limited pada 2025 Jun 30 adalah -0.23.
  • roic untuk Immutep Limited pada 2025 Jun 30 adalah -0.25.
  • croic untuk Immutep Limited pada 2025 Jun 30 adalah -0.17.
  • ocroic untuk Immutep Limited pada 2025 Jun 30 adalah -0.26.
Period End (TTM) ROA ROE ROIC (Tingkat Pengembalian Investasi Modal) CROIC OCROIC
2025-06-30 -0.22 -0.23 -0.25 -0.17 -0.26
2025-03-31 -0.22 -0.23 -0.25 -0.17 -0.26
2024-12-31 -0.35 -0.37 -0.22 0.20 -0.18
2024-09-30 -0.35 -0.37 -0.22 0.20 -0.18
2024-06-30 -0.30
2024-03-31 -0.53
2023-12-31 -0.35 0.34
2023-09-30 -0.29 0.32
2023-06-30 -0.42
2023-03-31 -0.41
2022-12-31
2022-09-30 0.00
2022-06-30 0.00 0.00
2022-03-31 0.00
2021-12-31 0.00
2021-09-30 -0.37 -0.46
2021-06-30 -0.64 -0.39 0.45 -0.23
2021-03-31 -0.61 -0.86 -0.38 0.45 -0.21
2020-12-31 -0.64 -0.98 -0.39 0.49 -0.21
2020-09-30 -0.48 -0.73 -0.29 0.31 -0.18
2020-06-30 -0.33 -0.55 -0.32 0.23 -0.26
2020-03-31 -0.36 -0.60 -0.34 0.05 -0.30
Gross Margins
  • marjin kotor untuk Immutep Limited pada 2025 Jun 30 adalah -8.52.
  • marjin bersih untuk Immutep Limited pada 2025 Jun 30 adalah -8.99.
  • marjin operasi untuk Immutep Limited pada 2025 Jun 30 adalah -10.22.
Margin Kotor
The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
Margin Keuntungan Bersih
Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
Margin Operasi
Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) Margin Kotor Margin Keuntungan Bersih Margin Operasi
2025-06-30 -8.52 -8.99 -10.22
2025-03-31 -8.52 -8.99 -10.22
2024-12-31 -9.81 -11.12 -12.12
2024-09-30 -9.81 -11.12 -12.12
2024-06-30
2024-03-31
2023-12-31
2023-09-30 -11.38 -11.82
2023-06-30 -11.38 -11.82
2023-03-31 -9.77 -10.21
2022-12-31
2022-09-30 0.00 0.00
2022-06-30 0.00 0.00
2022-03-31
2021-12-31
2021-09-30
2021-06-30 -3.46 -7.74 -5.09
2021-03-31 -2.55 -5.61 -3.79
2020-12-31 -1.67 -4.31 -3.01
2020-09-30 -0.86 -2.03 -1.70
2020-06-30 -0.48 -0.98 -1.10
2020-03-31 -0.55 -1.09 -1.17
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK)1506184
Grupong Pang-industriya
SIC 2834 - Pharmaceutical Preparations
Other Listings
AU:IMM A$ 0.24
DE:YP1B € 0.12
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista